Arthneeti
All Q1 FY27 results →
H

Hikal Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Hikal Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹204
Market cap₹2.7K Cr
P/E62.7
Updated28 Aug 2026
Read5 min read

Hikal Ltd Q1 FY27 key numbers

Revenue
Personal Care segment is a new growth driver, expected to cross Rs. 200 crores revenue in the next three years, with EBITDA margins over 20%.

As stated in Hikal Ltd's Q1 FY27 earnings call transcript · published 28 Aug 2026. Reported figures, not investment advice.

The short version

FY27 full-year growth expected to be approximately 14% to 16%, driven by strong pharma growth and marginal crop growth. - Pharma business projected to grow at 18% to 19% CAGR going forward, potentially faster with pending approvals and NCE filings. - Animal Health business targeted to reach Rs. Hikal expects a top-line CAGR of 15%-16% annually going forward, driven by strong growth in pharma (18%-19% CAGR) and marginal growth in crop. - EBITDA growth is projected at 25%-30% for FY27, with margins set to improve significantly from FY28 as FDA remediation costs cease. - The Animal Health business is targeted to reach Rs.

From Hikal Ltd's Q1 FY27 earnings-call transcript · updated 28 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • FY27 full-year growth expected to be approximately 14% to 16%, driven by strong pharma growth and marginal crop growth.
  • Pharma business projected to grow at 18% to 19% CAGR going forward, potentially faster with pending approvals and NCE filings.
  • Animal Health business targeted to reach Rs. 400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion.
  • Personal Care segment is a new growth driver, expected to cross Rs. 200 crores revenue in the next three years, with EBITDA margins over 20%.
  • Crop Protection business anticipates marginal, mid to high single-digit growth due to subdued pricing and demand pressures.

2 more points from Hikal Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Hikal Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Rs. 45 crores capex in Q1 FY27: focused on de-bottlenecking, regulatory upgrades, and building new capacities.
  • Over last 4 years, approx. Rs. 900 crores invested in capex: Rs. 300 crores for maintenance CAPEX (~Rs. 75 crores/year across 6 sites).
  • Rs. 600 crores invested in growth CAPEX:
  • Rs. 300 crores towards agrochemical manufacturing plant (part-impaired, now being retooled to reduce timelines by 12 months for Pharma/Animal Health portfolio).
  • Rs. 150 crores in dedicated Animal Health manufacturing site (validations completed, revenues started).
  • Rs. 100 crores in multipurpose manufacturing facility in Bangalore (already generating revenues).
  • New cGMP pilot plants commissioned improving R&D capabilities.
  • Commissioned dedicated multi-purpose manufacturing line at Panoli for Personal Care segment.

2 more points from Hikal Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company has several contracts in process, with 2-3 new contracts expected post U.S. FDA clearance.
  • Customer confidence remains strong; no contracts or customers have been lost in the last year despite FDA issues.
  • Multiple NCE (New Chemical Entity) campaigns and molecule programs are underway, reflecting a healthy order pipeline.
  • Animal Health business has long-term contracts with global innovators and repeat campaign orders.
  • Pharma CDMO business is building momentum with expanding customer engagement across North America, Europe, Japan, and emerging markets.
  • Discussions on strategic partnerships with Japanese companies are progressing well.
  • Pipeline includes around 8-9 molecules at various development stages toward commercialization.

2 more points from Hikal Ltd's call on order book

Create a free account to keep reading this call

What the Q1 FY27 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins up
CapexCapex planned
FundraiseNo fundraise planned

Hikal Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Hikal's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Hikal Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Hikal Ltd Q1 FY27 results?

FY27 full-year growth expected to be approximately 14% to 16%, driven by strong pharma growth and marginal crop growth. - Pharma business projected to grow at 18% to 19% CAGR going forward, potentially faster with pending approvals and NCE filings. - Animal Health business targeted to reach Rs. Hikal expects a top-line CAGR of 15%-16% annually going forward, driven by strong growth in pharma (18%-19% CAGR) and marginal growth in crop. - EBITDA growth is projected at 25%-30% for FY27, with margins set to improve significantly from FY28 as FDA remediation costs cease. - The Animal Health business is targeted to reach Rs.

What is Hikal Ltd share price analysis?

Hikal Ltd currently shows a below-average growth signal. The stock trades at a P/E of 62.7 with a market cap of ₹2,658 Cr. Investors should review the full earnings analysis for detailed insights.

Is Hikal Ltd planning capital expenditure?

Rs.

Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.